[All-trans retinoic acid combined with low-dose cytosine arabinoside treatment for acute myelogenous leukemia with trilineage myelodysplasia--a case report].
AML with trilineage myelodysplasia (AML/TMDS) is recognized as having of poor prognosis due to its resistance to chemotherapy in comparison with de novo AML. An AML/TMDS patient who failed to respond to ordinary induction therapy achieved complete remission with combination therapy consisting of all-trans retinoic acid (ATRA) and low-dose Ara-C. No serious toxicity was observed. ATRA combined with low-dose Ara-C could be an alternative treatment for this kind of patient.
Maeda
N
N
Dept. of Internal Medicine, Kakogawa Municipal Hospital.
Satake
S
S
Okada
Y
Y
Asahara
S
S
Hasuike
N
N
Tamura
M
M
Takata
M
M
Tasaka
K
K
Okutani
T
T
Maeda
Y
Y
Tomofuji
Y
Y
Chinzei
T
T
Saigo
K
K
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000150:complications* / Q000188:drug therapy*; D008875:Middle Aged; D009436:Neural Tube Defects / Q000150:complications / Q000188:drug therapy*; D014212:Tretinoin / Q000008:administration & dosage
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D003561:Cytarabine; D014212:Tretinoin